Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Results take time
FDA The FDA has not endorsed any alternative dosing protocol and has issued warnings about compounded GLP-1 formulations, which are often marketed for microdosing purposes
Two prior authorization policies required at least two comorbidities and 70% of policies specified the conditions
Incompletely established adverse effect profile : Although Phase 2 trial data (NEJM, 2023) provides some safety information, the full adverse effect profile of retatrutide has not yet been established through the complete Phase 3 programme
US$ 28.06
&srotate=0)
US$ 27.98
US$ 20.74
US$ 20.35
US$ 29.24
